Heterosexual AIDS Cases Up Sharply, But Numbers Remain Small

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

BETHESDA, Md--As expected, the number of reported AIDS cases increased substantially in 1993 due to the expansion of the surveillance case definition in January of that year, but an adjusted analysis shows only a slight overall increase.

BETHESDA, Md--As expected, the number of reported AIDS cases increasedsubstantially in 1993 due to the expansion of the surveillancecase definition in January of that year, but an adjusted analysisshows only a slight overall increase.

This analysis showed a 1993 incidence increase of 3% (62,000 casesin 1993 versus 60,000 in 1992). However, a slight decrease (1%)was seen in homosexual/bisexual men, while the AIDS incidencefor intravenous drug users increased by 8%, and for heterosexualsby 23% (MMWR 43:826-831, 1994).

Still, the number of persons infected through heterosexual contactremains small (7,500 in 1993), compared with the number infectedthrough homosexual sex (30,300) or IV drug use (17,800).

The report also showed significant geographic differences in AIDSincidence trends. Although the number of cases contracted throughheterosexual sex rose in all four regions of the country, theincreases varied widely, from 11% in the South to 39% in the Northeast.

The incidence among IV drug users increased in the Northeast,where most lived when diagnosed, but remained stable in the Southand West. The number of homosexual cases decreased in the Westwhile remaining stable in the Northeast, South, and Midwest.

Recent Videos
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Related Content